Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
Eli Lilly released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly list price to reach more patients without insurance coverage for the ...
Hosted on MSN1mon
PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFSThe phase III BREAKWATER study is evaluating the candidate's safety and efficacy in combination with Eli Lilly’s LLY Erbitux (cetuximab) and chemotherapy (mFOLFOX6) in mCRC patients harboring a ...
Hosted on MSN1mon
Pfizer's BRAFTOVI shows promise in colorectal cancer trialThey also see potential in Eli Lilly's orforglipron treatment ... been granted FDA approval for BRAFTOVI® in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal ...
The cost-effectiveness agency has backed the combination of Braftovi (encorafenib) and Eli Lilly's Erbitux (cetuximab) as a second-line treatment option for BRAF V600E mutated mCRC after an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback